Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-100 | 135-20-6 | Cupferron | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Positive | Positive | ADENOMA | Neoplastic Lesions |
| Yes | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Positive | Positive | (ADENOMA) | Neoplastic Lesions |
| Yes | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Positive | Positive | (ADENOMA) | Neoplastic Lesions |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 0/49 9/46 13/49 11/48 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/50 7/51 10/55 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| Yes | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/47 8/45 20/48 | Neoplastic Lesions |
| Yes | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/48 14/49 29/50 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/52 2/51 10/54 11/56 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/46 6/46 8/47 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/43 9/44 8/42 | Neoplastic Lesions |
| Yes | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Some Evidence | Some Evidence | ADENOMA 6/50 8/40 13/50 OR CARCINOMA 0/50 0/40 1/50 COMBINED 6/50 8/40 14/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| Yes | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 9/50 10/50 19/50 32/50 OR CARCINOMA 1/50 1/50 6/50 5/50 COMBINED 10/50 11/50 25/50 37/50 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| Yes | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 7/50 16/50 19/50 OR CARCINOMA 1/50 2/50 4/50 3/50 COMBINED 6/50 9/50 20/50 21/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50 | Neoplastic Lesions |
| Yes | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 10/50 10/50 25/50 23/50 ADENOMA OR CARCINOMA 11/50 10/50 26/50 25/50 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47 | Neoplastic Lesions |
| Yes | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 16/50 24/50 27/50 ADENOMA OR CARCINOMA 6/50 16/50 27/50 30/50 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 0/45 8/44 20/48 32/47 31/43 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/45 19/47 20/47 24/46 40/46 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 3/47 17/47 23/47 32/46 42/47 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47 | Neoplastic Lesions |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 6/50 11/50 14/49 19/51 adenoma or carcinoma 6/50 11/50 14/49 20/51 | Neoplastic Lesions |
| Yes | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | adenoma (2/50, 6/50, 6/50, 8/50); adenoma or adenocarcinoma (2/50, 6/50, 9/50, 8/50) | Neoplastic Lesions |
| Yes | TR-552 | 107-19-7 | Propargyl alcohol | Mice | B6C3F1/N | Male | Inhalation | Harderian Gland | Some Evidence | Equivocal Evidence | adenoma 3/50, 10/50, 6/50, 11/50 | May Have Been Related |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/50 7/51 10/55 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/52 2/51 10/54 11/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/49 0/47 1/52 2/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 0/50 2/48 1/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 20/49 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/50 6/49 12/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 5/50 21/50 36/49 29/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 1/59 0/60 4/60 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 0/60 0/59 3/60 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Brain | Clear Evidence | Clear Evidence | (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | Neoplastic Lesions |
| Yes | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Intestines (Small) | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Ovary | Clear Evidence | Clear Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Preputial Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Equivocal Evidence | NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Heart) | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | Neoplastic Lesions |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | May Have Been Related |
| No | TR-434 | 106-99-0 | 1,3-Butadiene | Mice | B6C3F1 | Male | Inhalation | Zymbal Gland | Clear Evidence | Equivocal Evidence | (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Forestomach | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50 | Neoplastic Lesions |
| Yes | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Equivocal Evidence | ADENOMA 0/51 0/53 1/51 3/55 1/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 3/50 2/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Equivocal Evidence | CARCINOMA 0/52 0/50 1/51 2/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 25/50 45/51 46/53 45/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA 1/51 2/53 4/51 3/53 3/59 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Seminal Vesicle | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/52 1/50 4/51 11/50 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Subcutaneous Tissue | Clear Evidence | Clear Evidence | FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Urinary Bladder | Clear Evidence | Clear Evidence | TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59 | Neoplastic Lesions |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Clear Evidence | Equivocal Evidence | HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50 | May Have Been Related |
| No | TR-452 | 3296-90-0 | 2,2-bis(Bromomethyl)-1,3-propanediol | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60 | Neoplastic Lesions |
| Yes | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Positive | Positive | (ADENOMA) | Neoplastic Lesions |
| Yes | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Male | Dosed-Feed | Harderian Gland | Positive | Positive | (ADENOMA) | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (NEOPLASTIC NODULE, CARCINOMA) | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Mice | B6C3F1 | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-205 | 101-80-4 | 4,4'-Oxydianiline | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 1/4 6/48 12/47 3/48 8/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 4/46 0/46 2/48 5/45 8/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 0/45 8/44 20/48 32/47 31/43 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 2/48 1/48 0/48 2/48 4/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 1/48 2/48 3/48 4/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 1/48 3/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 18/48 24/46 22/47 31/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Pancreas Islet Cell | Clear Evidence | Clear Evidence | adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 1/48 2/48 1/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48 | Neoplastic Lesions |
| No | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/50 6/50 24/50 19/50 SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 11/50 COMBINED 3/50 7/50 25/50 29/50 | Neoplastic Lesions |
| No | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/50 4/50 19/50 25/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 8/50 9/50 COMBINED 3/50 4/50 26/50 32/50 | Neoplastic Lesions |
| Yes | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 10/50 10/50 25/50 23/50 ADENOMA OR CARCINOMA 11/50 10/50 26/50 25/50 | Neoplastic Lesions |
| Yes | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 16/50 24/50 27/50 ADENOMA OR CARCINOMA 6/50 16/50 27/50 30/50 | Neoplastic Lesions |
| No | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Female | Gavage | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 6/50 6/50 14/50 9/50 | May Have Been Related |
| No | TR-506 | 107-13-1 | Acrylonitrile | Mice | B6C3F1 | Female | Gavage | Ovary | Clear Evidence | Equivocal Evidence | BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/50 0/50 4/50 1/50 | May Have Been Related |
| Yes | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 0/49 9/46 13/49 11/48 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 15/49 25/45 26/50 22/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 4/49 10/48 10/50 15/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 2/42 5/50 9/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 3/42 6/50 6/49 COMBINED 4/49 5/42 10/50 13/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/49 6/48 8/50 12/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 5/49 11/48 12/50 14/49 COMBINED 10/49 16/48 19/50 21/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/49 2/45 5/50 10/49; CARCINOSARCOMA 0/49 0/45 1/50 4/49 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 4/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 4/50 5/50 COMBINED 1/50 5/50 12/50 9/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 6/50 11/50 13/50 OR SQUAMOUS CELL CARCINOMA 0/50 3/50 5/50 7/50 COMBINED 1/50 9/50 16/50 19/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Ovary | Clear Evidence | Clear Evidence | BENIGN MIXED TUMORS 0/47 1/44 12/49 7/48; GRANULOSA CELL TUMOR 1/47 1/44 6/49 7/48 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/21 3/28 18/29 28/35 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 1/50 5/50; SQUAMOUS CELL CARCINOMA 0/50 5/50 3/50 8/50 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/43 0/32 1/37 3/31 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Mice | B6C3F1 | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/43 1/34 4/40 21/39 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/45 5/40 5/44 14/46 | Neoplastic Lesions |
| No | TR-289 | 71-43-2 | Benzene | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 2/32 6/46 10/42 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Forestomach | Clear Evidence | Clear Evidence | Squamous Cell Papilloma 0/50 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50 | Neoplastic Lesions |
| Yes | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Kidney Tubular Cell | Clear Evidence | Clear Evidence | (SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Lung | Clear Evidence | Equivocal Evidence | Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50 | May Have Been Related |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | CARCINOMA 3/50 4/50 7/50 12/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 24/49 32/50 36/50 36/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | SARCOMA 0/50 4/50 8/50 3/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 11/50 11/50 18/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Female | Inhalation | Urinary Bladder | Clear Evidence | Equivocal Evidence | TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50 | May Have Been Related |
| No | TR-467 | 126-99-8 | Chloroprene | Rats | F344/N | Male | Inhalation | Urinary Bladder | Clear Evidence | Equivocal Evidence | TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49 | May Have Been Related |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Vascular System (Unspecified) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Male | Inhalation | Vascular System (Unspecified) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50 | Neoplastic Lesions |
| No | TR-467 | 126-99-8 | Chloroprene | Mice | B6C3F1 | Female | Inhalation | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 0/50 3/50 | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Female | Dosed-Feed | Forestomach | Positive | Positive | SQUAMOUS CELL CARCINOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Male | Dosed-Feed | Forestomach | Positive | Positive | SQUAMOUS CELL CARCINOMA | Neoplastic Lesions |
| Yes | TR-100 | 135-20-6 | Cupferron | Mice | B6C3F1 | Female | Dosed-Feed | Harderian Gland | Positive | Positive | ADENOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Mice | B6C3F1 | Female | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOMA OR HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Mice | B6C3F1 | Male | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Female | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Male | Dosed-Feed | Vascular System (Unspecified) | Positive | Positive | HEMANGIOSARCOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Mice | B6C3F1 | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-100 | 135-20-6 | Cupferron | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Female | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Male | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/46 6/46 8/47 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/43 9/44 8/42 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 9/49 6/48 22/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/49 4/48 17/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 1/48 7/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 11/50 11/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 10/50 16/50 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/49 1/47 5/49 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | All Organs | Clear Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 4/48 6/48 7/48 11/48 14/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/45 3/48 10/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/48 3/48 10/47 17/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 1/45 1/45 1/47 5/45 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/48 1/48 0/48 0/47 3/46 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/45 19/47 20/47 24/46 40/46 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 3/47 17/47 23/47 32/46 42/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant schwannoma 2/48 3/48 3/48 7/47 8/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 26/48 35/48 33/48 36/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Equivocal Evidence | granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/47 3/48 6/47 13/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Forestomach | Some Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 1/49 2/50 5/49 | May Have Been Related |
| Yes | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Some Evidence | Some Evidence | ADENOMA 6/50 8/40 13/50 OR CARCINOMA 0/50 0/40 1/50 COMBINED 6/50 8/40 14/50 | Neoplastic Lesions |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Hematopoietic System | Some Evidence | Some Evidence | LEUKEMIA 14/50 29/50 24/50 | Neoplastic Lesions |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Nasal Cavity | Some Evidence | Equivocal Evidence | ADENOMA 0/48 0/47 2/49 | May Have Been Related |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Mice | B6C3F1 | Female | Gavage | Pituitary Gland | Some Evidence | Some Evidence | ADENOMA 10/47 15/45 24/46 | Neoplastic Lesions |
| No | TR-340 | 5634-39-9 | Iodinated glycerol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Some Evidence | Some Evidence | CARCINOMA 0/49 5/49 1/49 | Neoplastic Lesions |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Rats | F344/N | Female | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Rats | F344/N | Male | Gavage | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/47 8/45 20/48 | Neoplastic Lesions |
| Yes | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/48 14/49 29/50 | Neoplastic Lesions |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 3/50 4/50 17/49 | Neoplastic Lesions |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 8/50 4/50 19/50 OR CARCINOMA 6/50 13/50 12/50 COMBINED 12/50 17/50 26/50 | Neoplastic Lesions |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Female | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 4/50 7/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 5/50 7/49 COMBINED 6/50 8/50 13/49 | Neoplastic Lesions |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 6/50 11/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/49 4/50 10/50 COMBINED 5/49 10/50 18/50 | Neoplastic Lesions |
| No | TR-352 | 924-42-5 | N-Methylolacrylamide | Mice | B6C3F1 | Female | Gavage | Ovary | Clear Evidence | Clear Evidence | GRANULOSA CELL TUMOR 0/50 5/45 5/47 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Rats | F344/N | Male | Inhalation | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 7/50 16/50 19/50 OR CARCINOMA 1/50 2/50 4/50 3/50 COMBINED 6/50 9/50 20/50 21/50 | Neoplastic Lesions |
| Yes | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 9/50 10/50 19/50 32/50 OR CARCINOMA 1/50 1/50 6/50 5/50 COMBINED 10/50 11/50 25/50 37/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | ADENOMA 14/50 25/50 17/50 35/50 OR CARCINOMA 10/50 14/50 8/50 12/50 COMBINED 19/50 34/50 22/50 40/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 3/50 3/50 2/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 3/50 5/50 3/50 COMBINED 3/50 6/50 6/50 12/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR ADENOMA 11/50 10/50 9/50 12/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 3/50 3/50 11/50 COMBINED 13/50 13/50 12/50 20/50 | Neoplastic Lesions |
| No | TR-461 | 75-52-5 | Nitromethane | Rats | F344/N | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 19/50 21/50 33/50 36/50 OR CARCINOMA 2/50 7/50 1/50 11/50 COMBINED 9/50 25/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Rats | Harlan Sprague-Dawley | Female | Inhalation | Adrenal Gland Medulla | Some Evidence | Some Evidence | benign pheochromocytoma (0/49, 3/50, 4/50, 6/50) | Neoplastic Lesions |
| Yes | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | adenoma (2/50, 6/50, 6/50, 8/50); adenoma or adenocarcinoma (2/50, 6/50, 9/50, 8/50) | Neoplastic Lesions |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma (12/50, 14/50, 24/50, 34/50); hepatocellular carcinoma (7/50, 8/50, 12/50, 34/50); hepatoblastoma (0/50, 0/50, 1/50, 8/50) | Neoplastic Lesions |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Mice | B6C3F1 | Male | Inhalation | Liver | Clear Evidence | Clear Evidence | hepatocellular carcinoma (8/50, 19/50, 16/50, 35/50); hepatoblastoma (1/50, 1/50, 1/50, 15/50) | Neoplastic Lesions |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Rats | Harlan Sprague-Dawley | Male | Inhalation | Lung | Some Evidence | Equivocal Evidence | alveolar/bronchiolar adenoma or carcinoma (0/50, 2/50, 0/50, 3/50) | May Have Been Related |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Rats | Harlan Sprague-Dawley | Female | Inhalation | Thyroid Gland C-Cell | Some Evidence | Some Evidence | adenoma (2/50, 8/50, 8/50, 14/50) | Neoplastic Lesions |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Rats | Harlan Sprague-Dawley | Male | Inhalation | Thyroid Gland C-Cell | Some Evidence | Some Evidence | adenoma (2/50, 5/49, 3/49, 12/50) | Neoplastic Lesions |
| No | TR-594 | 98-56-6 | p-Chloro-a,a,a-trifluorotoluene | Rats | Harlan Sprague-Dawley | Female | Inhalation | Uterus | Some Evidence | Some Evidence | adenocarcinoma (1/50, 1/50, 0/50, 5/50); stromal polyp (7/50, 9/50, 16/50, 12/50) | Neoplastic Lesions |
| Yes | TR-552 | 107-19-7 | Propargyl alcohol | Mice | B6C3F1/N | Male | Inhalation | Harderian Gland | Some Evidence | Equivocal Evidence | adenoma 3/50, 10/50, 6/50, 11/50 | May Have Been Related |
| No | TR-552 | 107-19-7 | Propargyl alcohol | Mice | B6C3F1/N | Female | Inhalation | Nasal Cavity | Some Evidence | Some Evidence | adenoma, respiratory epithelium (0/50, 2/50, 4/50, 6/50) | Neoplastic Lesions |
| No | TR-552 | 107-19-7 | Propargyl alcohol | Mice | B6C3F1/N | Male | Inhalation | Nasal Cavity | Some Evidence | Some Evidence | adenoma, respiratory epithelium (0/49, 1/50, 4/50, 7/50) | Neoplastic Lesions |
| No | TR-552 | 107-19-7 | Propargyl alcohol | Rats | F344/N | Male | Inhalation | Nasal Cavity | Some Evidence | Some Evidence | adenoma, respiratory epithelium (0/49, 0/49, 0/50, 3/49) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 1/47 5/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 0/46 2/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/45 1/47 4/46 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 0/48 2/46 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45 | Neoplastic Lesions |
| Yes | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | malignant mesothelioma 1/50 12/50 18/50 37/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 3/50 1/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 4/50 3/50 | May Have Been Related |
| Yes | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 6/50 11/50 14/49 19/51 adenoma or carcinoma 6/50 11/50 14/49 20/51 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | hepatocellular adenoma 33/49 42/50 42/49 44/50 hepatocellular carcinoma 9/49 17/50 22/49 26/50 hepatoblastoma 0/49 1/50 4/49 6/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 36/49 44/50 43/49 46/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Mice | B6C3F1/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | hepatocellular carcinoma 12/50 22/50 27/49 39/51 hepatoblastoma 4/50 24/50 40/49 34/51 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 28/50 47/50 47/50 39/50 carcinoma 0/50 1/50 3/50 8/50 fibroadenoma, adenoma, or carcinoma 28/50 47/50 48/50 42/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | (oral mucosa and tongue): squamous cell papilloma or squamous cell carcinoma 1/50 0/50 3/50 3/50 | May Have Been Related |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma, keratoacanthoma, sebaceous gland adenoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma 9/50 7/50 15/50 21/50 | Neoplastic Lesions |
| No | TR-583 | 71133-14-7 | Water disinfection byproducts (Bromodichloroacetic Acid) | Rats | F344/NTac | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (subcutaneous tissue): fibroma 4/50 6/50 10/50 15/50 | Neoplastic Lesions |